Currently, the role of PROs and patient involvement in HTA is not well defined. This study aimed to define the role of PRO data and patient involvement in diabetes and obesity (two conditions of increasing global concern) and haemophilia (as an example of a rare disease). These three diseases serve as examples where PRO outcomes are not routinely used as primary outcomes to assess clinical efficacy.

Authors: Lee J, Kitchen H, Fletcher-Louis M

What drives the therapy selection test market?

View Now